Puma Biotechnology Stock Alpha and Beta Analysis
| PBYI Stock | USD 3.32 0.02 0.60% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Puma Biotechnology. It also helps investors analyze the systematic and unsystematic risks associated with investing in Puma Biotechnology over a specified time horizon. Remember, high Puma Biotechnology's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Puma Biotechnology's market risk premium analysis include:
Beta 1.47 | Alpha 0.43 | Risk 4.92 | Sharpe Ratio 0.0571 | Expected Return 0.28 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Puma |
Puma Biotechnology Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Puma Biotechnology market risk premium is the additional return an investor will receive from holding Puma Biotechnology long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Puma Biotechnology. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Puma Biotechnology's performance over market.| α | 0.43 | β | 1.47 |
Puma Biotechnology expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Puma Biotechnology's Buy-and-hold return. Our buy-and-hold chart shows how Puma Biotechnology performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Puma Biotechnology Market Price Analysis
Market price analysis indicators help investors to evaluate how Puma Biotechnology stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Puma Biotechnology shares will generate the highest return on investment. By understating and applying Puma Biotechnology stock market price indicators, traders can identify Puma Biotechnology position entry and exit signals to maximize returns.
Puma Biotechnology Return and Market Media
The median price of Puma Biotechnology for the period between Sat, Dec 14, 2024 and Fri, Mar 14, 2025 is 2.99 with a coefficient of variation of 8.24. The daily time series for the period is distributed with a sample standard deviation of 0.25, arithmetic mean of 3.06, and mean deviation of 0.19. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Puma Biotechnology Continuing To Push Their Aurora Kinase Story Forward - Seeking Alpha | 12/16/2024 |
2 | Disposition of 33841 shares by Alan Auerbach of Puma Biotechnology at 3.1517 subject to Rule 16b-3 | 01/02/2025 |
3 | Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635 | 02/05/2025 |
4 | Acquisition by Alan Auerbach of 274622 shares of Puma Biotechnology at 2.78 subject to Rule 16b-3 | 02/07/2025 |
5 | Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results | 02/13/2025 |
6 | Puma Biotechnology to Present at TD Cowens 45th Annual Health Care Conference | 02/26/2025 |
7 | Puma Biotechnology Non-GAAP EPS of 0.43 beats by 0.29, revenue of 59.1M beats by 6.6M | 02/27/2025 |
8 | Puma Biotechnology Inc Q4 2024 Earnings Call Highlights Revenue Growth and Strategic ... | 02/28/2025 |
9 | Are Investors Undervaluing Puma Biotechnology Right Now | 03/03/2025 |
10 | We Think Puma Biotechnologys Healthy Earnings Might Be Conservative | 03/07/2025 |
11 | European stocks set to steam ahead at the open on Ukraine ceasefire hopes U.S. inflation data ahead | 03/12/2025 |
12 | Disposition of 27241 shares by Alan Auerbach of Puma Biotechnology at 4.1779 subject to Rule 16b-3 | 03/14/2025 |
About Puma Biotechnology Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Puma or other stocks. Alpha measures the amount that position in Puma Biotechnology has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | Payables Turnover | 8.56 | 9.1 | 11.69 | 12.28 | Days Of Inventory On Hand | 29.98 | 41.23 | 49.44 | 52.91 |
Puma Biotechnology Upcoming Company Events
As portrayed in its financial statements, the presentation of Puma Biotechnology's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Puma Biotechnology's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Puma Biotechnology's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Puma Biotechnology. Please utilize our Beneish M Score to check the likelihood of Puma Biotechnology's management manipulating its earnings.
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Puma Biotechnology
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Puma Biotechnology Backtesting, Puma Biotechnology Valuation, Puma Biotechnology Correlation, Puma Biotechnology Hype Analysis, Puma Biotechnology Volatility, Puma Biotechnology History and analyze Puma Biotechnology Performance. For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Puma Biotechnology technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.